Editorial
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2025; 31(20): 105346
Published online May 28, 2025. doi: 10.3748/wjg.v31.i20.105346
Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass
Vasily Isakov
Vasily Isakov, Department of Gastroenterology and Hepatology, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow 115446, Russia
Author contributions: Isakov V wrote and edited the manuscript and reviewed the literature, read and approved the final version of the manuscript to be published.
Supported by Russian Science Foundation, No. 19-76-30014.
Conflict-of-interest statement: Isakov V has nothing to disclose.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Vasily Isakov, MD, PhD, Professor, Department of Gastroenterology and Hepatology, Federal Research Center of Nutrition, Biotechnology and Food Safety, 21 Kashirskoye Shosse, Moscow 115446, Russia. vasily.isakov@gmail.com
Received: January 20, 2025
Revised: April 13, 2025
Accepted: May 9, 2025
Published online: May 28, 2025
Processing time: 129 Days and 14.5 Hours
Core Tip

Core Tip: Skeletal muscle alterations, such as sarcopenia, myosteatosis, and altered muscle metabolism, are highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD) and are increasingly recognized as both contributors and consequences of MASLD, affecting disease progression and outcomes. Common treatment approaches for both conditions include nutritional interventions and physical activity/exercise aimed at increasing insulin sensitivity and reducing fat mass but maintaining muscle mass and function. Pharmacological agents that target the muscle and liver (such as glucagon-like peptide-1 receptor agonists) show promise, but have not yet been approved for the treatment of MASLD.